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Abstract: 
Significance: Diseases related to vascular malfunction, hyper-vascularization, or lack of 
vascularization are among the leading causes of morbidity and mortality. Engineered, 
vascularized tissues as well as angiogenic growth factor releasing hydrogels could replace 
defective tissues. Furthermore, treatments and testing of novel vascular therapeutics will benefit 
significantly from models that allow for the study of vascularized tissues under physiological 
relevant in vitro conditions.  
Recent Advances: Inspired by fibrin, the provisional matrix during wound healing, naturally-
derived and synthetic hydrogel scaffolds have been developed for vascular engineering. Today, 
engineers and biologists use commercially available hydrogels to pre-vascularize tissues, to 
control the delivery of angiogenic growth factors, and to establish vascular diseases models. 
Critical Issue: For clinical translation, pre-vascularized tissue constructs must be sufficiently 
large and stable to substitute function-relevant tissue defects and integrate with host vascular 
perfusion. Moreover, the continuous integration of knowhow from basic vascular biology with 
innovative, tailorable materials and advanced manufacturing technologies is key to achieving 
near-physiological tissue models and new treatments to control vascularization. 
Future Directions: For transplantation, engineered tissues must comprise hierarchically 
organized vascular trees of different caliber and function. The development of novel 
vascularization promoting or inhibiting therapeutics will benefit from physiologically relevant 
vessel models. Additionally, tissue models representing treatment-relevant vascular tissue 
functions will increase the capacity to screen for therapeutic compounds and will significantly 
reduce the need for animals for their validation. 
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1.0 Scope and Significance: Diseases related to vascular malfunctions are among the leading 
causes of morbidity and mortality in the industrialized world. While patients suffer from 
insufficient vascular perfusion of the heart, the brain, or even peripheral tissues, excessive 
vascular growth contributes to the pathogenesis of cancer, psoriasis, or diabetic retinopathy. 
Even though treatments towards insufficient perfusion by growth factor-mediated induction of 
angiogenesis have delivered promising results in basic research, clinical trials have not met 
expectations. Additionally, anti-angiogenic approaches towards the reduction of 
vascularization in most cancers have only resulted in the minimal extension of progression free 
survival. Obviously, relevant in vitro models to study blood vessel biology and treatment 
approaches under near-physiological conditions are needed. The engineering of vascularized 
tissue constructs for in vivo transplantation as well as for modeling diseases in vitro requires 
appropriate scaffold materials that support cell-specific functions and are compatible with 
innovative (micro)-manufacturing techniques. Extracellular matrix (ECM)-inspired hydrogels 
fulfill these requirements and are extremely versatile scaffold materials for vascular 
engineering. Importantly, essential to the success of vascular engineering is the continuous 
integration of hydrogel innovations with advances in vascular biology and manufacturing 
techniques. In this review, we discuss hydrogels in vascular engineering, including their in vivo 
application. We specifically focus on the advancements related to materials research and on the 
development of vascularized three-dimensional (3D) tissue models. 
2.0 Translational Relevance: The continuous integration of novel biomaterials and 
technologies with vascular biology and medicine is important for the success of vascular 
engineering. Furthermore, vascularized tissue models are based on hydrogel materials 
compatible with innovative 3D manufacturing techniques. Vascularized 3D models that 
resemble the complexity of differentiated human tissues will build an important base to study 
basic vascular biology, vascularized tissues, and novel therapeutics under fully controlled near-
physiological conditions. 
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3.0 Clinical Relevance: Clinical treatments to improve or inhibit vascularization using drug 
releasing materials were only partially successful and require further biological understanding 
and the improvement of current treatment concepts. Engineered, vascularized tissue units that 
are functional in vivo could be transplanted to treat ischemic tissues. Small, physiologically 
relevant 3D models of various tissues or cancers will enable the screening and testing of novel 
therapeutics under defined conditions and will provide a platform for personalized medicine 
approaches. Furthermore, novel 3D models could help to understand the progression of 
vascularization-related disease on the cellular level. 
 
4.0 Background/Overview 
4.1 Mechanisms of blood vessel development, maturation, and remodeling 
The cardiovascular system supplies almost all tissues with gas, nutrients, signaling molecules, 
and cells. Neovascularization, the formation of new blood vessels, is a fundamental part of 
tissue formation and repair involving two distinct morphogenetic processes: vasculogenesis and 
angiogenesis (Fig. 1A). Vasculogenesis denotes the de novo formation of blood vessels from 
mesodermal-derived precursor cells called angioblasts. The differentiation of angioblasts into 
endothelial cells and their subsequent assembly into a new primitive blood vessel network 
mainly occurs during embryonic development. Initially described to take place in the yolk sac 
of the developing mouse embryo, it became clear that blood vessel initiation by vasculogenesis 
independently occurs at both intra-embryonic and extra-embryonic sites of the embryo.1 
Interestingly, circulatory endothelial progenitor cells have been shown to enable vasculogenesis 
in the adult organism where they could play a significant role in tissue repair and regeneration.2-
4 Although relatively limited information on the molecular mechanism of vasculogenesis is 
available, genetic ablation studies showed that fibroblast growth factor (FGF)-2, bone 
morphogenetic protein (BMP)-4, and vascular endothelial growth factor (VEGF) are centrally 
involved in the process of vasculogenesis.5 In contrast, angiogenesis is the formation of new 
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blood vessels from preexisting ones and occurs throughout the whole lifespan. Sprouting 
angiogenesis describes the branching of endothelial cells from existing blood vessels due to the 
local environment’s provision of angiogenic signals.6-8 Intussusceptive angiogenesis occurs 
from the formation of pillars in the inside of preexisting capillaries resulting in their 
longitudinal division “within itself.”9 However, molecular mechanisms leading to 
intussusceptive angiogenesis remain largely obscure. 
Under homeostatic conditions small-caliber blood vessels are composed of an endothelial cell 
tube and perivascular cells. In this constellation, endothelial cells are quiescent and form stable 
interactions with each other and with a specialized ECM layer, the basement membrane.10 Upon 
metabolic demand or hypoxic conditions pro-angiogenic molecules, such as VEGF, FGF, 
platelet derived growth factor (PDGF)-BB, stromal cell-derived factor (SDF1)-α, and 
Angiopoietin (ANG)-2 become available in the local environment and cause the proteolytic 
remodeling of the vessel basement membrane, the destabilization of endothelial cell-cell 
contacts, and the extravasation of blood plasma proteins that contribute to the formation of a 
provisional ECM.11-13 Interestingly, inflammatory cells upon injury establish quite similar 
angiogenic growth factor milieus. Subsequently, some endothelial cells via VEGF receptor 
(VEGFR)-2 and VEGFR-3 mediated signaling acquire a tip cells phenotype, become motile, 
and form filopodia.14, 15 Tip cells upregulate the delta-like ligand (DLL)-4 that binds to the 
Notch receptor of neighboring endothelial cells where it suppresses the expression of VEGFR-
2 and VEGFR-3 and promotes the expression of VEGFR-1.15 As a consequence of the changed 
VEGFR expression, these cells become less responsive to VEGF-signals and exhibit a stalk cell 
phenotype showing stronger proliferation and the initiation of lumen formation. To form new 
vascular networks two tip cells undergo anastomosis, which is initiated by filopodia contacts 
and results in the fusion of different endothelial sprouts. 
Primitive endothelial tube maturation into mature vessels is initiated by the recruitment of 
perivascular cells that ultimately enwrap the endothelial tubes. Perivascular cells are of 
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mesenchymal origin and classified as pericytes or vascular smooth muscle cells depending on 
their localization to small or large vessels, respectively.16, 17 Among the factors known to play 
an important role in the recruitment, proliferation, and differentiation of perivascular cells are 
PDGF-BB, ANG-1, and transforming growth factor (TGF)-β. Due to their stabilizing and 
regulating role, perivascular cells are generally considered as vascular support cells. 
Additionally, debate continues over whether perivascular cells are mesenchymal tissue 
progenitor cells since these cells also reside in the perivascular microenvironment of blood 
vessels.18-24 
Angiogenesis is a partially overshooting process and endothelial cells become calmed by 
perivascular cells once in contact. However, overproduced or redundant vessels need to be 
pruned. The main cause of vessel regression is interrupted blood flow.25-27 Mechanistically, 
upon lumen collapse vessel regression is achieved by increased apoptosis or migration of 
endothelial cells.27-30 However, and conversely, the lumen collapse during vessels regression 
has also been shown to be the consequence of endothelial cell apoptosis.31 Furthermore, the 
finding that perivascular cells are actively involved in vessel pruning supports the idea that 
vessel regression is not a passive process.32 Remarkably, vessel formation and vessel pruning 
can occur simultaneously within the same vascular network.33 
 
4.2 Extracellular matrix as template for neovascularization during tissue repair  
Neovascularization is crucial to tissue development and homeostasis. Hence, 
neovascularization is also key to wound healing and tissue repair. The pivotal step of blood 
vessel establishment during wound healing is the recruitment of participating cells into the 
defective tissue. This cell recruitment requires a supportive matrix, which is established during 
the initial steps of wound healing by the release of fibrinogen, plasma fibronectin, and platelets 
from leaky blood vessels. The resulting fibronectin and platelet enriched fibrin clot acts as a 
temporary matrix for early healing promoting factors and supports the infiltration of cells.34 
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Subsequently, mobilized neutrophils and macrophages release growth factors into the matrix. 
Importantly, several angiogenic growth factors, such as VEGF-A, FGF-2, and PDGF-BB can 
bind to fibrin and fibronectin and thereby render the wound matrix a growth factor presentation 
platform.35-39 This angio-competent milieu attracts endothelial, perivascular, and stromal cells 
that, by secretion of cellular fibronectin and fibrillar collagen, remodel the initial fibrin clot into 
a provisional matrix. During tube formation, endothelial and perivascular cell types start to lay 
ECM components around the blood vessels and thereby establish the basement membrane of 
mature blood vessels. The main components of the basement membrane are collagen type IV, 
laminins, nidogens, fibronectin, and perlecan. However, many more ECM components, such as 
collagen type XV and XVIII and glycosaminoglycans contribute to the basement membrane.40, 
41 Besides providing structural and physical support to cells, the vascular ECM acts as a pro-
angiogenic signal transducer. The ECM composition itself exerts an instructive role for vascular 
development covering, e.g., early endothelial lumen formation, endothelial quiescence, and 
mature vessel stabilization.10, 40, 42, 43 On the other hand, the anti-angiogenic effects of collagen 
IV, XV, and XVIII cleavage products actively regulate blood vessel formation and stability.40, 
44 Since neovascularization is strongly associated with the dynamic remodeling of the ECM, 
enzymes that disintegrate ECM components are key regulators of neovascularization. Plasmin 
and the members of the large matrix metalloproteinase (MMP) family are proteases able to 
cleave ECM proteins. This proteolytic ECM breakdown enables three fundamental processes: 
1) disintegration of the basement membrane and cell-cell junctions resulting in breakout of 
endothelial and perivascular cells, 2) liberation of angiogenic growth factors from their ECM 
storage, and 3) turnover and maturation of the ECM during vessel formation and maturation. 
But, to achieve a strictly controlled degradability-stability equilibrium, the proteolytic activity 
of both plasmin and MMPs is controlled by direct counterparts, such as alpha 2-antiplasmin 
and tissue inhibitors of metalloproteinases (TIMP). 
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5.0 Hydrogels for Vascular Engineering 
Vascular-deficient tissues can be treated by either the delivery of angiogenic growth factors or 
the transplantation of pre-vascularized tissues. While the delivery of growth factors builds on 
the individual´s endogenous vascularization potential, the transplantation of pre-vascularized 
tissues is applicable even if the wound-healing cascade is strongly impaired. Looking at the 
natural processes of blood vessel development and regeneration, vascular engineering 
minimally requires angiogenic growth factors or vascular cells in combination with adequate 
3D scaffolds (Fig. 1B). Although completely scaffold-free strategies exist (e.g., spheroid or cell 
sheet technology45-47), most vascular engineering strategies require appropriate scaffolds that 
enable the transport of growth factors or cells and provide a 3D matrix for blood vessel 
(in)growth and formation (Fig. 1C).  
Hydrogel materials have become valuable 3D scaffolds for vascular engineering since they 
share many features with the natural ECM, including high water content and viscoelastic 
properties. Naturally occurring or synthetic polymers that are hydrophilic and form 
interconnected networks by physical interactions or chemical bonds can form hydrogels. By 
controlling the chemical properties of the polymer, its initial concentration and the distance 
between molecular interactions in the network, hydrogel parameters, such as stiffness, swelling, 
and pore size can be readily adapted.48, 49 To date, a variety of biocompatible, natural, or 
synthetic ECM-mimicking hydrogels are commercially available for a broad spectrum of users 
(see Caliari and Burdick50). Many of these hydrogel systems can be used to engineer pre-
vascularized tissue constructs in vitro prior to in vivo implantation by drawing the evolutionary 
memory of endothelial cells to assemble into micro-capillary networks when co-cultured with 
perivascular or other mesenchymal cells. 
 
5.1 Natural ECM hydrogels and modified ECM protein-based (semi-synthetic) hydrogels 
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The main class of hydrogel materials directly derived from natural ECM is protein polymers. 
Protein polymers’ great advantage is their intrinsic bioactivity, which includes the provision of 
cell adhesion and proteolytic degradable sites. Moreover, the application of ECM protein 
polymers has a long tradition in vascular biology and existing knowledge of this materials class 
is profound. Pioneering work in the 1980s from Nicosia et al. and Montesano et al. showed that 
fibrin and collagen type I hydrogels can host micro-capillary-like structures ex vivo.51-55 Based 
on this early work, ECM protein-based hydrogels have become the most widely used scaffold 
materials for vascular engineering. The first matrix vascular cells encounter during 
vascularization in vivo is fibrin. Fibrin hydrogels result from the enzymatic activation of 
fibrinogen by thrombin, followed by terminal factor XIIIa-mediated, enzymatic cross-linking. 
In vitro, fibrin hydrogels are suitable templates for endothelial and mesenchymal cells, which 
under appropriate co-culture conditions readily form micro-capillaries. Studies from different 
labs have proven that such in vitro established pre-vascularized fibrin constructs connect 
(inosculate) to the host vasculature when transplanted into mice.56-60 Importantly, one study 
provided experimental evidence for the general assumption that an in vitro pre-vascularization 
step is indeed beneficial over only cell delivery (Fig. 2).56 Collagen type I is part of the 
interstitial ECM and has the intrinsic capacity to self-assemble into hydrogels under 
physiological conditions. In a seminal series of in vitro studies, Davis and co-workers have 
shown that collagen hydrogels allow for the formation of 3D micro-capillary networks by 
endothelial and perivascular cells.61-65 Other studies showed that capillaries engineered within 
collagen hydrogels successfully inosculate after in vivo implantation.66-70 However, native 
collagen hydrogels might miss the optimal degradability-stability equilibrium since the low 
collagen concentrations suitable for 3D culture of micro-capillary networks result in 
mechanically weak scaffolds. To overcome this dilemma, collagen hydrogels have been 
modified by plastic compression71-73 or by chemical modifications as discussed below. 
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To combine their cell-instructive and biocompatible features with desired mechanical 
properties, natural ECM components can be tuned by chemical modifications. The resulting 
semi-synthetic biomaterials are beneficial, especially when using highly proteolytic cells as is 
the case in vascular engineering. In this regard, a photo-cross-linkable collagen-poly(ethylene 
glycol) (PEG) hybrid material, in which the mechanical properties could be increased 
independently of the material density, has been developed.74 Within this collagen-PEG 
hydrogel micro-capillary networks can be generated. Another promising and widely used ECM-
based material is gelatin, which is derived from collagens by hydrolytic breakage. Like its 
mother material, gelatin can form physical hydrogels of quite weak mechanical properties. 
Unfortunately, gelatin hydrogels are just stable below 37 °C, which makes them inappropriate 
as independent scaffolds. However, methacrylic anhydride modification renders gelatin into 
photo-cross-linkable gelatin methacrylate (GelMA) hydrogels of excellent tissue engineering 
properties.75-77 Using GelMA as vascularization scaffold, micro-capillary networks that 
anastomose with a murine host can be achieved either through in vitro pre-vascularization or 
subcutaneous injection of polymerizing hydrogel precursors and vascular cells.78, 79 These 
studies clearly demonstrate the benefits of chemically modified ECM polymers because the 
bioactivity of gelatin allowed for micro-capillary network formation and the photo-cross-link 
mechanism for stable material properties.  
 
5.2 Modified GAG-based (semi-synthetic) hydrogels and PEG-based (synthetic) hydrogels 
While natural and chemically modified ECM protein-based hydrogels are excellent substrates 
for the culture of vascularized tissues, they exhibit inherent materials properties. To gain further 
control over materials properties, carbohydrate-based materials, such as glycosaminoglycans 
(GAG) serve as the basis for hydrogel engineering. Upon modification with cross-linkable 
chemical groups, GAG hydrogels can be produced with defined physical properties. Although 
GAGs as components of the natural ECM are known to be degraded by enzymes, to bind growth 
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factors and to interact with cell-surface receptors, their modification with additional 
biologically functional modules, such as small peptides or protein domains is key for vascular 
engineering. As we can learn from hyaluronic acid (HA), two biological features from the 
natural ECM are required to turn these semi-synthetic scaffolds into cell-friendly hydrogels for 
neovascularization: sites for integrin-dependent cell adhesion and sites for proteolytic 
remodeling. Indeed, acrylated HA when modified with the cell-adhesion peptide arginine–
glycine–aspartic acid (RGD) and polymerized by a thiol-cross-linker containing MMP-
sensitive peptides results in a bioactive hydrogel, which allows cell adhesion and proteolytic 
remodeling.80 These HA hydrogel modifications are sufficient to enable in vitro formation of 
micro-capillary networks that upon in vivo transplantation anastomose with the host 
vasculature.81-84 Not surprisingly, hybrid hydrogels built by the cross-linking of the GAG 
heparin and poly(ethylene glycol) (PEG) can host micro-capillary networks when biologically 
modified by RGD and MMP-sensitivity.85, 86 However, in contrast to HA hydrogels, heparin-
based hydrogels through the high abundance of sulfate groups and the resulting negative charge 
enables the affinity binding of various growth factors. 
We have seen that hydrogels derived from naturally occurring ECM components are suitable 
scaffolds for vascular engineering, and that they can be engineered within a certain range 
towards desired functions. Reverse engineered synthetic hydrogels aim to mimic the natural 
ECM but rely on fully controlled design and synthesis.87-90 Since manufactured from scratch, 
synthetic hydrogel materials can be seen as blank slates free of animal products and 
confounding biological factors, per se. Conceivably, in these initially cell-inert synthetic 
materials biological modifications are essential to render them cell-friendly and biologically 
functional. Interestingly, it seems that the minimalistic approach of facilitating cell adhesion by 
RGD and matrix remodeling by MMP-sensitive peptides is generally sufficient for micro-
capillary network formation in synthetic hydrogels. Although these materials are still less used 
than natural ECM hydrogels, some work proving the potential of synthetic hydrogels for 
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vascular engineering has been reported within the last decade. Hydrogels exclusively composed 
of PEG allow neovascularization in vitro and in vivo when RGD sites and MMP-sensitivity 
optimized the material. In this regard, several studies showed that co-culturing of endothelial 
and mesenchymal cells in PEG hydrogels is a promising approach for the formation of 3D pre-
vascularized scaffolds with fully defined properties.91-94  
 
5.3 Controlled delivery of vascular endothelial growth factor by hydrogel immobilization  
In vitro engineered vascular networks hold great promise to become transplantable functional 
tissue units. However, their production relies on the expansion of autologous cells under 
complex production environments and is labor- and cost-intensive. By contrast, the concept of 
therapeutic angiogenesis builds on the idea that upon proper stimulation with key pro-
angiogenic factors, the body´s innate angiogenic program initiates the formation of new vessels. 
Early therapeutic angiogenesis attempts, conducted by the infusion of plasmid DNA encoding 
the expression VEGF or recombinant VEGF proteins into various tissue sites as well as into 
blood vessels, showed promising results in preclinical studies that could not be reproduced in 
clinical trials.95 To improve therapeutic angiogenesis by at least partially localized delivery, 
hydrogels with no or weak affinities for growth factors were employed for release by passive 
or slowed-down diffusion.96 In recent years, multiple sophisticated strategies that enable the 
tailoring of growth factor release towards specific requirements have been developed (for a 
comprehensive review see Briquez et al. 97). Here, we look at examples of VEGF delivery to 
demonstrate how hydrogel and growth factor engineering can boost the response of angiogenic 
growth factors.  
 An elegant strategy to functionalize fibrin hydrogels with growth factors has been developed 
by emulating the factor XIII (FXIII)-mediated cross-linking taking place in native fibrin. In 
detail, a short peptide sequence (NQEQVSPL) responsible for linking α2-plasmin inhibitor to 
fibrin allows the covalent XIIIa-mediated binding of growth factors to fibrin when fused to the 
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N-terminus of growth factors or peptides.98, 99 Resulting growth factor-modified fibrin 
hydrogels enable the release of their growth factor payload upon cell-mediated matrix 
degradation. Applying this engineering approach in vivo resulted in an improved angiogenic 
performance of fibrin-immobilized as compared to freely diffusible VEGF121 (Fig. 3A).100-102 
However, a considerable downside of fibrin hydrogels is their relatively fast degradation 
kinetics in vivo, resulting in the robust induction of new vessels that are not stabilized and 
regress due to the short duration of VEGF-treatment.102 Although this material´s degradability-
stability equilibrium related problem could be partially addressed by changing the fibrin 
amount, conceivably a higher material density is negatively correlated with vascular 
morphogenesis.103, 104 Therefore, degradation-resistant and VEGF-releasing fibrin hydrogels 
were engineered by modifying fibrin with the covalently bound fibrinolysis inhibitor aprotinin 
and VEGF164 at the same time (Fig. 3B). These long-lasting fibrin hydrogels enable a cell-
demanded, continuous, and slow release of VEGF164 and were shown to induce the formation 
of lasting blood vessels in skeletal muscles and to improve the perfusion of ischemic hind-limbs 
and skin flaps in mice.105 
Another way of controlling the stability of growth factor releasing hydrogels is to engineer them 
from the bottom-up using defined components. The degradability of synthetic PEG hydrogels, 
for instance, can be tailored by introducing peptide sequences with variable sensitivities for the 
proteolytic degradation by MMPs and Plasmin.106, 107 For in situ vascularization, different 
VEGF-variants were immobilized to cell-free, MMP-sensitive PEG hydrogels and liberated by 
host cells.108, 109 These studies showed that for synthetic hydrogels, bound VEGF outperformed 
soluble VEGF in inducing neovascularization in vivo in a qualitative as well as quantitative 
way. 
Current efforts to immobilize growth factors to hydrogels are directed towards more flexible 
engineering strategies. On the one hand, the binding of various native growth factors could be 
achieved by modifying hydrogels, for example with fibronectin domains, fibrinogen derived 
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peptides, or heparin.110-112 On the other hand, growth factors were engineered with affinities 
such that they bind to hydrogels comprising ECM-components, streptavidin, or barnase.113-115 
 
5.4 Limitations of current hydrogel-based vascularization strategies  
Despite tremendous progress in hydrogel-based vascularization strategies, major problems have 
emerged from the application of hydrogels as scaffolds for vascularized tissues. So far, except 
for skin, which is a relatively thin tissue, only small-size constructs have been successfully pre-
vascularized and implanted in vivo, due mostly to limitations in fabrication techniques and the 
soft material properties of cell-friendly hydrogels. Nevertheless, soft hydrogels can be applied 
as a gelatinous cell carrier solution within porous and solid scaffolds. For instance, endothelial 
and perivascular cells can be suspended in fibrinogen or matrigel solutions and poured into 
macroporous sponges prior to gel polymerization. Applying this technique in poly(lactic-co-
glycolic acid)/poly(L-lactic acid) co-polymers-based sponges facilitated the establishment of 
pre-vascularized capillary networks, which were shown to anastomose in vivo.116, 117 Although 
overcoming the stability problems of soft hydrogels, such a scaffold-in-scaffold strategy still 
relies on the “spontaneous” self-assembly of mono-dispersed cell mixtures, which per default 
result in micro-capillaries with diameters of about 10 µm. However, clinical relevant tissue 
constructs of large size require large-caliber vessels as well.  
For therapeutic angiogenesis, a substantial repertoire of angiogenic growth factors is known 
today. However, knowledge on the spatiotemporal availability and dynamics of growth factors 
(often described as 4th dimension) in tissues is still quite limited and remains a major challenge. 
Although it is widely accepted that growth factors appear in gradients resulting from diffusion 
and binding to the ECM, the characteristics of these growth factor gradients are highly complex, 
tissue-specific, and therefore difficult to determine. Furthermore, for the engineering of specific 
tissue factors controlling vascularization as well as factors directing differentiation need to be 
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present at the same time. Hence, potential cross-talks between angiogenic and tissue specific 
signals and cells need to be considered. 
 
6.0 Novel (hydrogel-based) Technologies for Vascularized Tissue Models  
In vascular biology, much knowledge has been generated using various well established in vivo 
evaluations and transgenic animal models.118, 119 Additionally, cellular and molecular 
mechanism controlling capillary architecture, morphogenesis, and EC-perivascular cell 
communication have been dissected in 3D in vitro systems using natural ECM hydrogels. 
Furthermore, engineered micro-capillary networks or molecules with blood vessel-modulating 
functions have been delivered in vivo using hydrogels. Yet, large caliber vessels are still 
missing in current pre-vascularization systems. Furthermore, while angiogenesis inhibitors 
proved successful for the treatment of ocular vascular diseases, their use for cancer treatments 
in many instances did not lead to the targeted effects.120, 121  
The study of basic vascular biology, the development of novel therapeutic strategies, and the 
establishment of in vitro platforms for personalized therapies will benefit from physiologically 
relevant and reproducible 3D tissue models. Since novel materials and manufacturing 
technologies are key to achieve such models, we will discuss their impact on the generation of 
vascularized tissue models in the next sections. 
 
6.1 Synthetic hydrogel materials to study basic vascular biology  
The American Heart Association states that collagen type I and fibrin hydrogels are the gold 
standard materials for 3D in vitro vascular biology assays.122 Indeed, these systems have 
provided invaluable insight into the morphogenesis of blood vessel capillaries. However, 
biological outcomes might be influenced by ECM hydrogel properties. In contrast, semi-
synthetic and synthetic hydrogels enable study of the function of ECM components on vascular 
morphogenesis and signaling in the absence of confounding ECM signals. Such defined 
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conditions will further allow control over growth factor presentation and the evaluation of 
growth factor gradients, for example during sprouting angiogenesis and pericyte recruitment.123 
The in vitro recapitulation of angiogenic processes under controlled matrix and growth factor 
presentation conditions will be important to the study of spontaneous morphogenic processes 
and associated molecular and biochemical functions. A recent publication shows the adequacy 
of fully synthetic hydrogels to provide insights into the heterocellular communication between 
perivascular and endothelial cells.124 Moreover, in synthetic hydrogels established vascular 
models could provide a platform to manipulate morphogenic processes by using sophisticated 
and ideally remotely controllable cells and materials components as they are becoming 
available.125, 126 For example, cells that upon chemical-, temperature-, or light-mediated 
activation induce the expression of angiogenic stimuli, receptors, or even cell-cell adhesion 
molecules could be used to study cellular communication during vessel formation and 
remodeling. Furthermore, hydrogels whose stiffness, cell adhesion, or growth factor binding 
properties can be modulated by light could serve to control the local activation of sprouting 
angiogenesis.  
 
6.2 Vascularized models of specific types of tissues  
Vessel properties vary among different tissues and reciprocally vessels can influence the 
development and function of tissues. Therefore, vessel functions should be studied in tissue 
specific models consisting of multiple properly arranged and differentiated cell types. Since 
they are relatively simple in structure, dermo-epidermal tissue models were among the first 
engineered differentiated tissues with an established functional vascularization.58, 59 However, 
in tissues with high structural complexity, the localization of growth factor stimulation relies 
on a spatial patterning to prevent a potential interference of different signaling cues. The need 
for the spatial separation of growth factors has been shown in engineered bone and bone marrow 
mimicking environments, as they require at least two different growth factors.94 While the 
18  
osteogenic signal BMP-2 directed mesenchymal progenitor cells towards osteogenic 
commitment, FGF-2 supported the maintenance of an undifferentiated phenotype. Since in this 
system both factors promote the formation of a 3D micro-capillary network, the localized 
presentation of the factors could be used to study vascular functions responsible for the 
maintenance of hematopoietic stem cells in their bone marrow compartment.   
 
6.3 Vascularized cancer models  
Cancer is known to continuously promote angiogenesis and to benefit from excessive 
vascularization. Therefore, the inhibition of angiogenesis was considered as a strategy to reduce 
cancer progression. Surprisingly, the treatment of cancer patients with VEGF inhibitors in many 
instances did result only in the minimal extension of progression free survival.127 The cause of 
limited treatment efficiency can be manifold and includes the compensation of treatment effects 
through non-angiogenic mechanisms. Nevertheless, mechanisms also related to angiogenesis, 
such as the co-option of preexisting vessel structures or the compensation for the lack of one 
angiogenic cue by the upregulation of another cue, are currently seen as important aspects to 
be carefully studied. Moreover, within the last decade, the dogma of vascularization-based 
cancer treatment has shifted from the inhibition of blood vessel formation to a normalization of 
the structurally and functionally aberrant cancer induced blood vessels.128 Due to the enormous 
need for meaningful in vitro screening assays, 3D models of cancer have become one of the 
fastest growing research topics in both cancer biology and tissue engineering. Since 
angiogenesis is one of the hallmarks of cancer, vascularization has been integrated into 
engineered 3D cancer models. While first vascularized cancer models were established in 
naturally occurring ECM hydrogels, models engineered in semi-synthetic and synthetic 
hydrogels are now becoming available and have the potential to give rise to highly structured, 
vascularized tumor environments.129-133  
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6.4 Manufacturing channels in hydrogels to engineer large caliber vessels  
Vascular engineering can benefit from novel biofabrication techniques, such as bioprinting, 
micro-molding and lithography, in moving towards the development of larger diameter vessels. 
By applying these techniques, hydrogel materials that contain imbedded channels of several 
hundred micrometers can be obtained. Subsequently, the created channels can be lined by 
endothelial cells and can serve as potential access sites for perfusion. For example, Bertassoni 
et al. have molded channels into stiff GelMA and PEG hydrogels using agarose rods and seeded 
the channels with endothelial cell suspensions after removing the rods.134 In two other studies, 
gold rods coated with oligopeptides and ECs have been used to couple channel creation and 
endothelialization. After hydrogel formation, the endothelial cells were electrochemically 
transferred from the gold rod to the hydrogel and thereby formed an endothelialized channel.135, 
136 Another strategy to establish endothelialized channels is to combine micro-molding and 
additive manufacturing as excellently shown in collagen hydrogels.137, 138 The general concept 
of leaving behind a channel in hydrogels can also be implemented by printing temperature 
dissolvable materials into temperature stable hydrogels and release them on demand by an 
adequate temperature shift.139-141 To save labor, channels can be created in hydrogels by laser-
based photo-ablation of the bulk hydrogel material, a technique that renounces molding and 
allows for high spatiotemporal control over the channel design.142 Independent of the 
fabrication method and the employed material, the channel-based vascularization concept holds 
great potential for tissue engineering applications. But, the transfer of big channels to in vivo 
applications remains to be realized. 
 
6.5 Microfluidic technology for the perfusion of vascularized tissue models  
Today, most vascularization models are still based on non-perfused micro-capillary networks. 
Factors that control flow-mediated vessel maturation and remodeling are not accessible in non-
perfused systems and consequently cannot be studied. Additionally, drugs distributed using the 
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vasculature cannot be the tested in non-perfused systems. Therefore, novel vascularization 
models build on the formation of 3D vascular structures in microfluidic devices, which can be 
perfused with cell culture medium and permit the testing of pro- and anti-angiogenic 
compounds. Large channels can be formed, as we discussed in section 6.4, and connected to 
microfluidic devices. When such microfluidic channels are fused with micro-capillary networks 
the whole engineered vascularized model can be perfused.143-146 Conceivably, the dominant 
field in microfluidics perfused tissue models is cancer.147 In this regard, vascularized 
microtumors (VMT) have been generated in hydrogels.148, 149 When such VMT models were 
connected to perfusion, they allowed for the efficient screening of anti-cancer drugs that are 
affecting the microtumors as well as the tumor vasculature (Fig. 4). Furthermore, the 
combination of large vascular structures with self-arranged micro-capillaries would allow for 
the formation of hierarchically organized vascular trees.  
 
6.6 Outlook: Standardized platforms for drug screening and personalized medicine  
The above-described approaches to engineer vessel models are mainly designed to gain insight 
into physiological and pathological tissue functions. By using human cells, engineered vessel 
models avoid species-related false positive and negative results and therefore are interesting 
alternatives to preclinical animal models. However, to speed up the development of novel 
vascular drugs, the integration of vessel models with reproducible high throughput platforms is 
required. The potential benefit of such platforms was recently shown by using induced 
pluripotent stem cells and PEG hydrogels. 150 Since similar assays could be run with adult stem 
or induced pluripotent stem cells derived from healthy or diseased human individuals, these 
assays can also help to bring forward personalized medicine in the field of vascular diseases. 
 
7. Summary 
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Engineered pre-vascularized tissues and the delivery of angiogenesis promoting or inhibiting 
therapeutics are promising approaches to treat diseases related to malfunction of the 
vasculature. Additionally, emerging vascularized tissue models (summarized in Fig. 5) enable 
the study of basic vessel biology under near-physiological and pathology mimicking conditions 
in vitro. If scalable, vascularized tissue models would allow screening for therapeutic 
compounds under controlled and highly standardized conditions. The development of next-
generation vascularized tissues critically depends on hydrogel systems tailorable towards cell-
specific functions and compatible with innovative (micro)-manufacturing technologies. 
Therefore, the development of novel clinically translatable vascular treatments as well as 
personalized tissue models require the continuous integration of knowhow from basic vascular 
biology, hydrogel engineering, biofabrication, and medical needs. 
 
Take home messages 
• While pro- and anti-angiogenic treatments have shown promising results in basic 
research, clinical trials have not met expectations 
• ECM-inspired hydrogels are scaffold materials allowing for the engineering of 
vascularized tissues. 
• The main limitation of engineered pre-vascularized tissues is the lack of large vessels. 
• Physiologically relevant vascularized tissue models will enable the study of diseases as 
well as the testing of therapeutics under controlled in vitro conditions. 
• Hydrogel systems with defined and tunable materials properties are key for the 
development of innovative 3D tissue models. 
• Future personalized, vascularized tissues and disease models depend on the continuous 
integration of knowhow from basic vascular biology, hydrogel engineering, 
biofabrication, and medical needs. 
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Figure legends: 
Figure 1: Engineering neovascularization in hydrogels inspired by the template function 
of the extracellular matrix (ECM) during blood vessel development and maturation. A) 
The establishment of new blood capillaries occurs through vasculogenesis and angiogenesis in 
an angio-competent milieu generated by growth factors and the ECM. B) Tools for vascular 
engineering derived from the natural processes of blood vessel development include vascular 
cells, growth factors, and ECM-inspired hydrogel scaffolds. Hydrogels can be engineered from 
natural ECM components or synthetic ECM analogues. C) Hydrogel-based strategies to 
generate new functional vascular networks in vivo. Pre-vascularization follows the concept of 
engineering vascular networks within hydrogels in vitro by the application of endothelial cells 
that self-assemble into micro-capillary networks. Upon transplantation, pre-vascularized 
hydrogel constructs can anastomose to the host vasculature and become perfused. In an 
alternative strategy, the delivery of soluble, matrix bound, or on demand releasable angiogenic 
growth factors can promote the formation of new vessels in situ.  
 
Figure 2: Pre-vascularization of fibrin hydrogels leads to the rapid anastomosis of 
engineered micro-capillaries with the host vasculature. Micro-capillaries were engineered 
in vitro by the co-culture of human fibroblasts with human umbilical vein endothelial cells 
(HUVEC) in fibrin hydrogels. Pre-vascularized tissue (A, 7 days in vitro pre-culture) was 
perfused by host blood cells more rapidly than non-pre-vascularized tissue (B, 1 day in vitro 
pre-culture) upon implantation. C) HUVEC-cultures in the absence of supporting fibroblasts do 
not form perfusable structures. Histological tissue sections from 3–14 days post-implantation, 
with red blood cells being evident in the pre-vascularized tissue starting at day 5 post-
implantation. MT, mouse tissue; IT, implant tissue. Scale bars: 100 mm. Adapted figure from 
Chen et al.56 with re-print permission. 
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Figure 3: In situ neovascularization by engineered, hydrogel-immobilized VEGF delivery. 
A) Skin vascularization response to ﬁbrin hydrogels containing no VEGF (control), soluble 
VEGF, or engineered, fibrin-immobilized VEGF. Although the immobilized VEGF 
outperforms soluble VEGF, the vascularization response decreases as the fibrin hydrogel 
becomes degraded over time. Figure re-print from Largo et al.102 B) Improvement of fibrin-
immobilized VEGF treatment by aprotinin engineered, long-lasting fibrin hydrogels. No VEGF 
(control) or engineered, fibrin-immobilized VEGF (0.5 μg/mL and 5 μg/mL) were compared in 
a hindlimb ischemia mouse model. Fibrin hydrogels used for the delivery were stabilized by 
fibrin-immobilization of the fibrinolysis inhibitor aprotinin. Tissues analyzed 4 weeks after 
hydrogel delivery for endothelial cells (CD31, in red), pericytes (NG2, in green), and smooth-
muscle cells (α-SMA, in cyan, scale bar: 20 μm) or for microcirculation by Laser-Doppler-
Imaging of non-ischemic and ischemic limbs (left and right legs, respectively). Figure re-print 
from Sacchi et al.105 
 
Figure 4: Perfused vasculature on-a-chip model as potential cancer and drug screening 
platform. A) Vascular networks formed by co-culture of human endothelial colony forming 
cells (ECFC-EC) and human fibroblasts in fibrin hydrogels. Vascular networks inside the three 
tissue chambers connect to microfluidic channels and can be perfused (70 kDa FITC-dextran). 
B) Vascularized microtumors (VMTs). HCT116 cancer cells were embedded together with 
endothelial/fibroblast co-cultures into fibrin hydrogels and grow into microtumors surrounded 
by perfused vascular networks. Scale bars: 100 μm. C) VMTs used for anti-cancer drug 
screening. The collapse of the tumor (vasculature) can be monitored upon treatment with FDA-
approved anti-cancer drugs. Adapted figure from Phan et al.148 with re-print permission. 
 
Figure 5: Engineering of vascularized tissue models using hydrogels.  
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Vascularized tissue models largely depend on engineered hydrogel-based, cell-instructive 
microenvironments. The culture of adult (stem) cells in these cell-instructive 
microenvironments enables the study of basic vascular biology under defined in vitro 
conditions. Engineering physiologically relevant human tissue and cancer models requires the 
integration of knowhow from vascular biology and biofabrication techniques. In the future, the 
use of defined 3D culture systems together with patient derived cells will allow for the screening 
of therapeutics and the testing for treatment towards personalized medicine. 
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